Interviews

Dr John Sweetenham: Issues Persist Among Medicare Beneficiaries for Reimbursement of CAR-T Therapy
December 07, 2019 – 
Reimbursement for CAR-T therapy has progressed to where commercially insured patients obtain coverage regularly, but issues remain for patients with Medicare, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.
Dr John McMurray Details the Preliminary Cost-Effectiveness Distinction of Dapagliflozin
December 07, 2019 – 
Cost-effectiveness analyses have not been conducted on the DAPA-HF trial as of yet, but in healthcare systems in which dapagliflozin is not particularly expensive, results are likely to be favorable, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Aliza Ben-Zacharia Provides Insight on Biosimilars for Treatment of Patients With MS
December 06, 2019 – 
Biosimilars have the potential to reduce costs of treatment for patients with MS, but until clinical trials show their efficacy, clinicians will feel uneasy about prescribing them for chronic illnesses, said Aliza Ben-Zacharia, DNP, ANP, associate director at the Center for Nursing Research and Innovation at Mount Sinai.
Dr Richard Snyder Offers Key Features of Value-Based Agreements
December 04, 2019 – 
Richard Snyder, MD, executive vice president of Facilitated Health Networks and chief medical officer at Independence Blue Cross, discusses key features that payers should include when implementing a value-based agreement.
Vanessa Sammy Discusses the Importance of Partnerships for Accomplishing Disruption
December 03, 2019 – 
Partnerships are essential for overcoming the barriers to implementing value-based care, explained Vanessa Sammy, MPA, MHSA, senior director of commercial strategy and implementation for Remedy Partners.
Dr Melinda Magyari Addresses the Use of Disease-Modifying MS Therapies in Children
December 02, 2019 – 
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure
November 30, 2019 – 
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Dr John Sweetenham Outlines the Effect of Current Policies on the Implementation of CAR T Therapy
November 29, 2019 – 
There are a number of policy changes that can drive change within the implementation of chimeric antigen receptor T-cell therapy, but further innovation is warranted to improve access, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center.
Aliza Ben-Zacharia Details Necessary Policies to Improve Affordability of MS Treatment
November 29, 2019 – 
Stronger intervention by the government in controlling price, accessibility, and availability of MS treatment can drive innovation, said Aliza Ben-Zacharia, DNP, ANP, associate director at the Center for Nursing Research and Innovation at Mount Sinai.
Bradley Prechtl on How Community Oncologists Can Work With Employers
November 27, 2019 – 
Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network discusses how Florida Cancer Specialists is working with employers.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.